Vivos Inc (QB) (RDGL) News

They won't. 

If I were the CEO the day after Trump is sworn in would be a perfect time for the PR, the Market will be up and a new era of prosperity will start for America!

What about 60million share offering?

There’s always a chance they release news premarket tomorrow.

IMO .25 at end of month unless we receive a huge blockbuster pr before the end of month.
Then the sky actually is the limit ...

Go CEO DR KORENKO and Mayo clinic with ISOPET

With a high probability of a very good PR on opening Tuesday next week Looks like tomorrow will be the last opportunity to pick up shares below $.16 Go $ RDGL

Getting closer........

I've definitely done that.



RDGL

I need to break out 0.50 first this month.

Who valued it at that?

Think Dividends if Radiogel doesn't sell !!!

And Telix has been on quite the buying spree lately.

Consultant for Telix pharmaceuticals TLX on nasdaq

Your math stinks .50 cents a share if RDGL sold at 250 million $1.00 dollar a share if sold at 500 million Our good CEO would be looking for way more for a worldwide treatment for cancer.

we get .12 a share :)

I missed you

LOL, AtlasQ doing what he does best ......overstretched thinking! Not like he hasn't been wrong multiple times on here.👇️

I would prefer a scenario where Telix buys the current offering. Is this a possibility?

Sorry that is not realistic; licensing seems a possibility as Korenko most likely will do for other world regions. That being said, I don't see Korenko selling to any outfit other than a US big pharmaceutical (assuming BO is his ultimate choice).

That could very well be the case, Looks like they acquired several companies last year and spent about $250M. Big Question is, for how much?

Yeah..., Telix will buy rdgl out and there goes your big pharama dream

Telix is company Sandip works for: https://media.licdn.com/dms/image/v2/D5610AQGqEIQxsPjBiw/image-shrink_1280/image-shrink_1280/0/1712616178965?e=1737648000&v=beta&t=rpqLjBhmQuEO2ThpxDqvAY3uNaJN6GKXiJuuJ-ZQN8E

India economy booming

https://twitter.com/marionawfal/status/1879911487818670510?s=46&t=MxR4z7pPou_0usGfqAHGvQ

Excellent move. Also pretty much confirms initial trials on the 5 patients went well. Otherwise this move would not be happening.

Consultants are never on payroll.... Business partner is what I have questions about

Yeah I read that, but vivos said "business partner". I do not know what to think of it.

Says he’s a consultant in this link

https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTA5ODY0&Enc=&userName=

Yep he is a REP imho as well

Okay, business partner...

That's better yet, now Doc doesn't have to put him on payroll and we still get same quality service. Smart idea.

Nice try at deception though.



RDGL

Could Business Partner = shareholder?
Lol

- Go $RDGL

It says "Business partner" it's not exactly a hire...

We may also get some tax harvesting sellers getting back in towards the end of January. Could add fuel to the fire and really move up the share price if we get some well timed PR's  and updates . 

Looks like RDGL and MAYO clinic with CEO DR KORENKO are making excellent progress....good year here

way ahead of fudsters and Elmer's glue stick

Looks like a good hire:

We are delighted to announce that Mr. Sandip Bali has joined our organization as a business partner to spearhead our international expansion efforts. With over two decades of expertise in the fields of radiotherapy, radioembolization, and interventional oncology, Mr. Bali has an extensive track record of driving business development across the Middle East, Africa, and Asia. His professional journey includes leadership roles at esteemed organizations such as Nordion Inc., Sirtex Medical, Novoste Corporation, and Telix Pharmaceuticals India.

Mr. Bali brings unparalleled expertise in navigating regulatory landscapes and advancing non-uranium production methodologies within the radioisotope industry. He will play a pivotal role in penetrating new markets, establishing strategic alliances, and enhancing our global presence. His deep understanding of the industry and proven business development acumen align seamlessly with our mission to innovate and achieve sustainable growth in the field of radiopharmaceuticals.

Thanks for the link. Solid proof and info on India trials.

What are the thoiughts on Sandip?

https://twitter.com/vivosincusa/status/1879898757250310404?s=46&t=MxR4z7pPou_0usGfqAHGvQ

IMHO, from the link Chereb posted, is that it has. RDGL 1st Human Trial
Dates of Record in India:
- Target Sample Size: 30
- Date of First Enrollment: January 07, 2024 (last year)
- CTRI Number: June 24, 2024 (Date Registered on)
- Primary Outcome TimePoints: day 0, day 1, day 7, month 1, month 3, month 12 (before and after therapy measurements)

As of today, last modified date is Christmas Eve 2024.
First 5 Patients TimePoint PR

It seems to me as though the expansion to 30 patients from 5 reflects a target patient number treated per week/ Y90 gel manufacturing run.
Conservatively, if Day 1 TimePoint triggered the company PR, then week after next we could see the Month 1 data, late March we get Month 3 data, and there could be rolling updates of the other 25 patients treatment journey as they follow their own cohort timeline.

Its up to Dr. K how he proceeds with FDA IDE of course, but if cohort 1 Month 1 dataset is favorable (Y90 inert, tumor reducing, no adverse effects, etc...), I would apply for Human Trials in US by February and could reasonably expect to be moving forward by March/April in the US while processing the India Month 3 data.

The 1 year timeframe for the India Human Trials means December of 2025 the first human trials cohort should start wrapping up. Folks who bought shares here for Christmas will then get their Capital Gains tax break if they claim profits on our product/tech and there would be a rolling group up to 30 stretching into March 2026 with FDA IDE human trials 12 month effort also concluding around April 2026... sound about right? Buying now to April n holding for 1 year n a day is what some folks seem to be doing.

- Go $RDGL

I agree.

TradersQue actively marketing Vivos' collaboration with the FDA very likely indicates Vivos is close to resubmitting its IDE application to gain FDA approval for US human trials.

On 6 October 2024, TradersQue's posted and eventually deleted a message promoting Vivos' efforts to resubmit the IDE application very likely after realizing that the FDA discussions would take longer than initially thought. TraderQue's 6 October 2024 public communication in support of Vivos' resubmission of the IDE application was posted a week prior to Vivos' anticipated completion date of the initial five Sprint Discussions with the FDA in 2024.

TradersQue did not post any marketing messages in support of Vivos' efforts to gain FDA approval to begin US human trials from 8 October 2024 to 14 January 2025. TradersQue actively marketing Vivos' collaboration with the FDA very likely indicates Vivos is close to resubmitting its IDE application to gain FDA approval for US human trials.

The 45 day Sprint Discussion deadline to reach an agreement on all issues between Vivos and the FDA review team was likely 14 January 2025. The two month mark for when the validation of the new sterility process will be completed is 20 January 2025.

I wouldn’t be surprised if the trial for the 30 patients has started already.

As soon as they have the data the FDA is looking for they can resubmit and it won’t even take the full 30 days to approve.

https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTA5ODY0&Enc=&userName=

I wonder if the Muppet sceeate has read this excerpt from the linked article in Post# 183312 yet!?!?!.................


Quote: "The company remains in active discussions with the FDA to initiate trials at the Mayo Clinic. Data from the Indian study will support the Investigational Device Exemption (IDE) submission and aim to strengthen the therapy’s safety profile. This dual international approach is designed to accelerate the global rollout of this innovative treatment."

This is what I got with a similar request:

India radiogel cancer trial......................added trial

ChatGPT said:

ChatGPT

India has been conducting trials for innovative cancer treatments, including the use of radiogel technology, to target tumors more effectively with fewer side effects. Radiogel is a type of injectable gel that contains radioactive particles. The idea behind this therapy is to precisely deliver radiation to a tumor site with minimal exposure to surrounding healthy tissue.

In a typical radiogel therapy, the gel is injected directly into or near the tumor. It then releases radiation over a period, allowing for targeted destruction of cancer cells. This approach offers several potential benefits over traditional external beam radiation, including better control over the dose delivered and the ability to treat tumors that might be difficult to reach with conventional methods.

India has seen several advancements in the development of such technologies, including the creation of radiogels that have shown promising results in animal models and early-stage human trials. The goal is to improve the efficacy and safety of cancer treatment, especially for patients who may not be candidates for surgery or conventional radiation.

These trials are part of a broader push in India to innovate and develop affordable cancer therapies, considering the growing cancer burden in the country. However, as with any new treatment, radiogel therapy will undergo rigorous clinical trials to evaluate its safety, efficacy, and long-term outcomes.

If you're referring to a specific trial or development within India, let me know, and I can provide more detailed information!


Maybe they are updating for the best!!!

https://twitter.com/quetraders/status/1879702981375111487?s=46&t=MxR4z7pPou_0usGfqAHGvQ

https://x.com/quetraders/status/1879661936360763596?s=46&t=vL-KXYXZYnhJDJaIoa-ARw

Thank you Ballajs for your very informative posts good times are coming for not only shareholders but for victims of cancer treated with Radiogel !!!

I asked AI (chatgpt) - India radiogel cancer trial. Below is what it responded.

Current Trials and Research in India:

India has been conducting clinical trials to explore the safety and efficacy of radiogel in treating various cancers, particularly for head and neck cancers, liver cancer, and prostate cancer. Some trials have shown promising results in improving local tumor control with fewer side effects compared to conventional treatments.
Challenges and Limitations:

Long-term Efficacy: Research is still ongoing to determine the long-term effectiveness of radiogel treatment.
Availability: The technology is not yet widely available and may be limited to specific hospitals or cancer treatment centers.
Cost: Radiogel-based treatments might be expensive, limiting accessibility in resource-constrained settings.
Notable Trials and Institutions:
Several Indian Institutes of Technology (IITs) and cancer research centers are collaborating on trials involving radiogel, especially in partnership with pharmaceutical companies focused on radiopharmaceuticals.
Institutes such as the Tata Memorial Centre, All India Institute of Medical Sciences (AIIMS), and Apollo Hospitals are exploring the use of radiogel for certain types of cancers.
Potential for Broader Use:
As clinical trials continue and the technology improves, radiogel therapy has the potential to revolutionize localized cancer treatment in India and around the world. It holds particular promise for cases where surgery is not an option, or when conventional radiation therapy would lead to unacceptable side effects.